MG Monthly Digest · No. 01 · September 2026
Skim it in two minutes, or read every word
This is the first one — built at the kitchen table, between MyChart notifications and school pickup, so if it reads a little raw in places, that’s on purpose. Filter it by what applies to you, and switch the depth whenever your energy changes.
On the Radar This Month
Four dates between now and October 3.
- Sept 23 · WebinarMGFA: Learn About IMAAVY® (nipocalimab-aahu)
A patient/caregiver session on this treatment’s clinical data, what starting it looks like, and where to find support.
- Sept 26 · New York CityMG Walk
If you’re local, this is community you can stand in, not just scroll past.
- Sept 29 · Orlando2026 MGFA Scientific Session
Aimed at researchers and clinicians, but it’s where next year’s patient-facing news gets its start.
- Oct 3 · Washington, D.C. + TorontoMG Walk & Community Health Fair
Toronto is with Muscular Dystrophy Canada. Early heads-up so you can plan.
The paperwork nobody warns you about
This is what “treatment options” actually looks like on a Tuesday morning — eight pages of medication list, five bottles, and a starter pack I’m still learning the rhythm of.
Everything below is written from this counter. That’s the whole reason this digest exists: the news only matters once it fits into the routine you’re already carrying.A major MG drug trial just finished enrolling patients.
Phase 3 UPSTREAM MG is fully enrolled — telitacicept, a monthly injection, tested in generalized MG. Results expected in the first half of 2027.
Vor Bio announced on September 8 that it has completed enrollment in UPSTREAM MG, a global Phase 3 trial testing telitacicept in generalized MG. It’s being tested as another option beyond what’s currently approved, and the company also announced plans to start a separate trial for ocular MG. Slow-moving news, but it’s one more shot on goal for our community.
IMAAVY keeps showing staying power.
New data shows symptom control holding past two years of follow-up — including people earlier in their disease course.
IMAAVY (nipocalimab-aahu) is an infusion approved for adults and teens (12+) with AChR- or MuSK-positive gMG. Johnson & Johnson shared new data this year showing patients stayed in symptom control for over two years of follow-up — not just the sickest patients. If you’re curious whether it fits your treatment picture, MGFA’s Sept 23 webinar (above) is a good, no-pressure way to learn more before you ever bring it up with your neurologist.
“Copay accumulators” — the quiet reason your assistance card stopped helping.
Some plans pocket your manufacturer copay assistance instead of counting it toward your deductible. NORD’s one-pager tells you what to ask.
Some insurance plans use programs called copay accumulators that let them pocket your manufacturer copay assistance instead of counting it toward your deductible — so you hit a wall of full-price bills later in the year, with no warning. NORD tracks which states have banned this and explains exactly what to ask your insurer or HR department. Five minutes of reading that could save you a very bad afternoon on the phone in November.
Reminder: My VYVGART Path exists, and it’s not small.
Eligible commercially-insured patients can pay as little as $0 out of pocket — up to $25,000 a year in assistance.
If you’re on VYVGART or VYVGART Hytrulo, argenx’s patient support program can bring eligible commercially-insured patients down to as little as $0 out of pocket, up to $25,000 a year in assistance. If nobody at your infusion center has walked you through this, ask — don’t assume you’ve already been offered everything you qualify for.
Advancing MG Research: From Discovery to What’s Next
A decade of patient-funded pilot grants — and a study that asked patients, not doctors, what treatment tradeoffs they’ll accept.
A look at how a decade of patient-funded pilot grants through Conquer MG has shaped real research — B cells, antibody pathways, and a study that specifically asked patients what tradeoffs they’re actually willing to make with treatment. Worth reading if you’ve ever wondered where research money really goes.
This year’s MGNet pilot grant just started.
Funding began September 15, aimed at better biomarkers and understanding MG subtypes. Seed money, not a breakthrough.
MGNet — a federally-funded rare disease research network partnered with MGFA, MGA, and Conquer MG — funds one “pilot” study a year to test a promising new idea before it’s big enough for major funding. This year’s award is aimed at finding better biomarkers (blood tests that could someday help predict how someone’s MG will behave) and understanding our different subtypes. It’s not a breakthrough. It’s the seed money that sometimes becomes one.
A tiny cellular messenger researchers are watching closely.
Exosomes — tiny delivery trucks our cells send out — are being studied as an earlier, less invasive way to track MG activity.
A new review rounds up what’s known about exosomes — think of them as delivery trucks our cells send out, carrying little signals about what’s happening inside. Researchers are studying whether they could someday become an earlier, less invasive way to track MG disease activity than what we have now. Nothing you can get tested for yet — but a direction worth knowing exists.
Bring this to your appointment
👉 Screenshot this month’s Financial & Access cards and bring them to your next appointment — even if it’s not until next month.
Sources
- Vor Bio, GlobeNewswireVor completes enrollment of global Phase 3 UPSTREAM MG trial and expands telitacicept franchise into ocular MG. Read the release
- Johnson & JohnsonNew IMAAVY (nipocalimab-aahu) data presented at EAN 2026 Congress. Read the release
- NORD (National Organization for Rare Disorders)Copay Accumulators one-pager. Open the PDF
- argenx / VYVGART.comCost and coverage, My VYVGART Path. See the program
- Conquer Myasthenia GravisAdvancing MG Research: From Discovery to What’s Next. Read the article
- MGNet / Rare Diseases Clinical Research NetworkMG Pilot Grant program. See the grant
- Cells (journal) — Ejdys & Mycko, 2026Review of exosomes in myasthenia gravis. doi.org/10.3390/cells15080679
Standing resources
- NORD copay accumulator one-pagerRe-check any time your coverage changes.
- My VYVGART PathOngoing argenx patient assistance program.
- MGFA events finder & calendarAlways-current Walks, webinars, and health fairs.
- Conquer MG patient assistanceStanding help for patients on other therapies.
Your Turn
Got a question, a term you want explained, or something you saw that I missed? Send it my way — next month’s digest might answer it.
I write this from the other side of an ICU bed and more MyChart messages than I can count — not from a medical degree. This is what I’ve learned, not medical advice. Your care team knows your body. I just know what it’s like to live in one that stopped listening to you.